Document is current
Any future updates will be listed below
-
Authors
Marsili, Luca https://orcid.org/0000-0002-6438-9911
Abanto, Jesus
Marcucci, Samuel B.
Duque, Kevin R.
Chirra, Martina
LaPorta, Joseph
VanDusen, Hannah
Paruchuri, Neha
Shaik, Ayesha
Wise-Draper, Trisha
Espay, Alberto J.
Vogrig, Alberto
- License Information
-
More Information
Article History
Received: 11 September 2025
Revised: 9 November 2025
Accepted: 20 November 2025
First Online: 4 December 2025
Declarations
:
: This research was not funded by any commercial or governmental agency. Luca Marsili has received honoraria from the International Association of Parkinsonism and Related Disorders (IAPRD) Society for social media and web support, and personal compensation as a consultant/scientific advisory board member for Acadia, ExpertConnect, Tegus, and Mirum Pharmaceuticals. Dr. Marsili has received a grant (collaborative research agreement) from the International Parkinson and Movement Disorders Society for the MDS-UTRS Validation Program (role: PI), non-profit. Jesus Abanto, Samuel Marcucci, Kevin R. Duque, Martina Chirra, Joseph LaPorta, Hannah VanDusen, Neha Paruchuri, and Ayesha Shaik have nothing to disclose. Trisha Wise-Draper has received funding for clinical trials from Merck & Co, BMS, Astra Zeneca, and GSK. She has received compensation as a consultant for Merck. Alberto Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, Abbvie, Bial, Kyowa Kirin, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc. (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” He cofounded REGAIN Therapeutics to fund preclinical studies, but relinquished the right to any personal income from future treatments. Alberto Vogrig is supported by the grant GR-2021-12375527 (“NEURO-CHECKMATE”) from the Italian Ministry of Health. He has received personal compensation for serving on a Speakers Bureau for Angelini and Eisai.
